<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d199" origId="Fenofibrate"><sentence id="DrugDDI.d199.s0" origId="s0" text="Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH TRICOR."><entity id="DrugDDI.d199.s0.e0" origId="s0.p0" charOffset="0-19" type="drug" text="Oral Anticoagulants"/><entity id="DrugDDI.d199.s0.e1" origId="s0.p6" charOffset="53-75" type="drug" text="COUMARIN ANTICOAGULANT"/><entity id="DrugDDI.d199.s0.e2" origId="s0.p9" charOffset="107-113" type="drug" text="TRICOR"/><pair id="DrugDDI.d199.s0.p0" e1="DrugDDI.d199.s0.e0" e2="DrugDDI.d199.s0.e1" interaction="?"/><pair id="DrugDDI.d199.s0.p1" e1="DrugDDI.d199.s0.e0" e2="DrugDDI.d199.s0.e2" interaction="?"/><pair id="DrugDDI.d199.s0.p2" e1="DrugDDI.d199.s0.e1" e2="DrugDDI.d199.s0.e2" interaction="?"/></sentence><sentence id="DrugDDI.d199.s1" origId="s1" text="THE DOSAGE OF THE ANTICOAGULANTS SHOULD BE REDUCED TO MAINTAIN THE PROTHROMBIN TIME/INR AT THE DESIRED LEVEL TO PREVENT BLEEDING COMPLICATIONS."><entity id="DrugDDI.d199.s1.e0" origId="s1.p11" charOffset="18-32" type="drug" text="ANTICOAGULANTS"/><entity id="DrugDDI.d199.s1.e1" origId="s1.p20" charOffset="112-119" type="drug" text="PREVENT"/><pair id="DrugDDI.d199.s1.p0" e1="DrugDDI.d199.s1.e0" e2="DrugDDI.d199.s1.e1" interaction="?"/></sentence><sentence id="DrugDDI.d199.s2" origId="s2" text="FREQUENT PROTHROMBIN TIME/INR DETERMINATIONS ARE ADVISABLE UNTIL IT HAS BEEN DEFINITELY DETERMINED THAT THE PROTHROMBIN TIME/INR HAS STABILIZED."/><sentence id="DrugDDI.d199.s3" origId="s3" text="HMG-CoA reductase inhibitors The combined use of TRICOR and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination."><entity id="DrugDDI.d199.s3.e0" origId="s3.p36" charOffset="0-28" type="drug" text="HMG-CoA reductase inhibitors"/><entity id="DrugDDI.d199.s3.e1" origId="s3.p37" charOffset="49-55" type="drug" text="TRICOR"/><entity id="DrugDDI.d199.s3.e2" origId="s3.p39" charOffset="60-88" type="drug" text="HMG-CoA reductase inhibitors"/><entity id="DrugDDI.d199.s3.e3" origId="s3.p51" charOffset="214-218" type="drug" text="drug"/><pair id="DrugDDI.d199.s3.p0" e1="DrugDDI.d199.s3.e0" e2="DrugDDI.d199.s3.e1" interaction="?"/><pair id="DrugDDI.d199.s3.p1" e1="DrugDDI.d199.s3.e0" e2="DrugDDI.d199.s3.e2" interaction="?"/><pair id="DrugDDI.d199.s3.p2" e1="DrugDDI.d199.s3.e0" e2="DrugDDI.d199.s3.e3" interaction="?"/><pair id="DrugDDI.d199.s3.p3" e1="DrugDDI.d199.s3.e1" e2="DrugDDI.d199.s3.e2" interaction="?"/><pair id="DrugDDI.d199.s3.p4" e1="DrugDDI.d199.s3.e1" e2="DrugDDI.d199.s3.e3" interaction="?"/><pair id="DrugDDI.d199.s3.p5" e1="DrugDDI.d199.s3.e2" e2="DrugDDI.d199.s3.e3" interaction="?"/></sentence><sentence id="DrugDDI.d199.s4" origId="s4" text="Resins Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption."><entity id="DrugDDI.d199.s4.e0" origId="s4.p52" charOffset="0-6" type="drug" text="Resins"/><entity id="DrugDDI.d199.s4.e1" origId="s4.p54" charOffset="13-35" type="drug" text="bile acid sequestrants"/><entity id="DrugDDI.d199.s4.e2" origId="s4.p57" charOffset="51-56" type="drug" text="drugs"/><entity id="DrugDDI.d199.s4.e3" origId="s4.p63" charOffset="98-104" type="drug" text="TRICOR"/><entity id="DrugDDI.d199.s4.e4" origId="s4.p68" charOffset="149-158" type="drug" text="bile acid"/><pair id="DrugDDI.d199.s4.p0" e1="DrugDDI.d199.s4.e0" e2="DrugDDI.d199.s4.e1" interaction="?"/><pair id="DrugDDI.d199.s4.p1" e1="DrugDDI.d199.s4.e0" e2="DrugDDI.d199.s4.e2" interaction="?"/><pair id="DrugDDI.d199.s4.p2" e1="DrugDDI.d199.s4.e0" e2="DrugDDI.d199.s4.e3" interaction="?"/><pair id="DrugDDI.d199.s4.p3" e1="DrugDDI.d199.s4.e0" e2="DrugDDI.d199.s4.e4" interaction="?"/><pair id="DrugDDI.d199.s4.p4" e1="DrugDDI.d199.s4.e1" e2="DrugDDI.d199.s4.e2" interaction="?"/><pair id="DrugDDI.d199.s4.p5" e1="DrugDDI.d199.s4.e1" e2="DrugDDI.d199.s4.e3" interaction="?"/><pair id="DrugDDI.d199.s4.p6" e1="DrugDDI.d199.s4.e1" e2="DrugDDI.d199.s4.e4" interaction="?"/><pair id="DrugDDI.d199.s4.p7" e1="DrugDDI.d199.s4.e2" e2="DrugDDI.d199.s4.e3" interaction="?"/><pair id="DrugDDI.d199.s4.p8" e1="DrugDDI.d199.s4.e2" e2="DrugDDI.d199.s4.e4" interaction="?"/><pair id="DrugDDI.d199.s4.p9" e1="DrugDDI.d199.s4.e3" e2="DrugDDI.d199.s4.e4" interaction="?"/></sentence><sentence id="DrugDDI.d199.s5" origId="s5" text="Cyclosporine Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration."><entity id="DrugDDI.d199.s5.e0" origId="s5.p72" charOffset="0-12" type="drug" text="Cyclosporine"/><entity id="DrugDDI.d199.s5.e1" origId="s5.p74" charOffset="21-33" type="drug" text="cyclosporine"/><entity id="DrugDDI.d199.s5.e2" origId="s5.p81" charOffset="104-110" type="drug" text="rises"/><entity id="DrugDDI.d199.s5.e3" origId="s5.p87" charOffset="195-208" type="drug" text="fibrate drugs"/><entity id="DrugDDI.d199.s5.e4" origId="s5.p89" charOffset="219-225" type="drug" text="TRICOR"/><pair id="DrugDDI.d199.s5.p0" e1="DrugDDI.d199.s5.e0" e2="DrugDDI.d199.s5.e1" interaction="?"/><pair id="DrugDDI.d199.s5.p1" e1="DrugDDI.d199.s5.e0" e2="DrugDDI.d199.s5.e2" interaction="?"/><pair id="DrugDDI.d199.s5.p2" e1="DrugDDI.d199.s5.e0" e2="DrugDDI.d199.s5.e3" interaction="?"/><pair id="DrugDDI.d199.s5.p3" e1="DrugDDI.d199.s5.e0" e2="DrugDDI.d199.s5.e4" interaction="?"/><pair id="DrugDDI.d199.s5.p4" e1="DrugDDI.d199.s5.e1" e2="DrugDDI.d199.s5.e2" interaction="?"/><pair id="DrugDDI.d199.s5.p5" e1="DrugDDI.d199.s5.e1" e2="DrugDDI.d199.s5.e3" interaction="?"/><pair id="DrugDDI.d199.s5.p6" e1="DrugDDI.d199.s5.e1" e2="DrugDDI.d199.s5.e4" interaction="?"/><pair id="DrugDDI.d199.s5.p7" e1="DrugDDI.d199.s5.e2" e2="DrugDDI.d199.s5.e3" interaction="?"/><pair id="DrugDDI.d199.s5.p8" e1="DrugDDI.d199.s5.e2" e2="DrugDDI.d199.s5.e4" interaction="?"/><pair id="DrugDDI.d199.s5.p9" e1="DrugDDI.d199.s5.e3" e2="DrugDDI.d199.s5.e4" interaction="?"/></sentence><sentence id="DrugDDI.d199.s6" origId="s6" text="The benefits and risks of using TRICOR with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed"><entity id="DrugDDI.d199.s6.e0" origId="s6.p102" charOffset="32-38" type="drug" text="TRICOR"/><entity id="DrugDDI.d199.s6.e1" origId="s6.p103" charOffset="44-62" type="drug" text="immunosuppressants"/><pair id="DrugDDI.d199.s6.p0" e1="DrugDDI.d199.s6.e0" e2="DrugDDI.d199.s6.e1" interaction="?"/></sentence><sentence id="DrugDDI.d199.s7" origId="s7" text="."/><sentence id="DrugDDI.d199.s8" origId="s8" text="? Drug-drug interactions In vitro studies using human liver microsomes indicate that fenofibrate and fenofibric acid are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2."><entity id="DrugDDI.d199.s8.e0" origId="s8.p118" charOffset="85-96" type="drug" text="fenofibrate"/><entity id="DrugDDI.d199.s8.e1" origId="s8.p120" charOffset="101-116" type="drug" text="fenofibric acid"/><entity id="DrugDDI.d199.s8.e2" origId="s8.p123" charOffset="139-149" type="drug" text="cytochrome"/><entity id="DrugDDI.d199.s8.e3" origId="s8.p125" charOffset="151-154" type="drug" text="CYP"/><entity id="DrugDDI.d199.s8.e4" origId="s8.p127" charOffset="156-160" type="drug" text="P450"/><entity id="DrugDDI.d199.s8.e5" origId="s8.p128" charOffset="178-184" type="drug" text="CYP2D6"/><entity id="DrugDDI.d199.s8.e6" origId="s8.p129" charOffset="186-192" type="drug" text="CYP2E1"/><entity id="DrugDDI.d199.s8.e7" origId="s8.p131" charOffset="197-203" type="drug" text="CYP1A2"/><pair id="DrugDDI.d199.s8.p0" e1="DrugDDI.d199.s8.e0" e2="DrugDDI.d199.s8.e1" interaction="?"/><pair id="DrugDDI.d199.s8.p1" e1="DrugDDI.d199.s8.e0" e2="DrugDDI.d199.s8.e2" interaction="?"/><pair id="DrugDDI.d199.s8.p2" e1="DrugDDI.d199.s8.e0" e2="DrugDDI.d199.s8.e3" interaction="?"/><pair id="DrugDDI.d199.s8.p3" e1="DrugDDI.d199.s8.e0" e2="DrugDDI.d199.s8.e4" interaction="?"/><pair id="DrugDDI.d199.s8.p4" e1="DrugDDI.d199.s8.e0" e2="DrugDDI.d199.s8.e5" interaction="?"/><pair id="DrugDDI.d199.s8.p5" e1="DrugDDI.d199.s8.e0" e2="DrugDDI.d199.s8.e6" interaction="?"/><pair id="DrugDDI.d199.s8.p6" e1="DrugDDI.d199.s8.e0" e2="DrugDDI.d199.s8.e7" interaction="?"/><pair id="DrugDDI.d199.s8.p7" e1="DrugDDI.d199.s8.e1" e2="DrugDDI.d199.s8.e2" interaction="?"/><pair id="DrugDDI.d199.s8.p8" e1="DrugDDI.d199.s8.e1" e2="DrugDDI.d199.s8.e3" interaction="?"/><pair id="DrugDDI.d199.s8.p9" e1="DrugDDI.d199.s8.e1" e2="DrugDDI.d199.s8.e4" interaction="?"/><pair id="DrugDDI.d199.s8.p10" e1="DrugDDI.d199.s8.e1" e2="DrugDDI.d199.s8.e5" interaction="?"/><pair id="DrugDDI.d199.s8.p11" e1="DrugDDI.d199.s8.e1" e2="DrugDDI.d199.s8.e6" interaction="?"/><pair id="DrugDDI.d199.s8.p12" e1="DrugDDI.d199.s8.e1" e2="DrugDDI.d199.s8.e7" interaction="?"/><pair id="DrugDDI.d199.s8.p13" e1="DrugDDI.d199.s8.e2" e2="DrugDDI.d199.s8.e3" interaction="?"/><pair id="DrugDDI.d199.s8.p14" e1="DrugDDI.d199.s8.e2" e2="DrugDDI.d199.s8.e4" interaction="?"/><pair id="DrugDDI.d199.s8.p15" e1="DrugDDI.d199.s8.e2" e2="DrugDDI.d199.s8.e5" interaction="?"/><pair id="DrugDDI.d199.s8.p16" e1="DrugDDI.d199.s8.e2" e2="DrugDDI.d199.s8.e6" interaction="?"/><pair id="DrugDDI.d199.s8.p17" e1="DrugDDI.d199.s8.e2" e2="DrugDDI.d199.s8.e7" interaction="?"/><pair id="DrugDDI.d199.s8.p18" e1="DrugDDI.d199.s8.e3" e2="DrugDDI.d199.s8.e4" interaction="?"/><pair id="DrugDDI.d199.s8.p19" e1="DrugDDI.d199.s8.e3" e2="DrugDDI.d199.s8.e5" interaction="?"/><pair id="DrugDDI.d199.s8.p20" e1="DrugDDI.d199.s8.e3" e2="DrugDDI.d199.s8.e6" interaction="?"/><pair id="DrugDDI.d199.s8.p21" e1="DrugDDI.d199.s8.e3" e2="DrugDDI.d199.s8.e7" interaction="?"/><pair id="DrugDDI.d199.s8.p22" e1="DrugDDI.d199.s8.e4" e2="DrugDDI.d199.s8.e5" interaction="?"/><pair id="DrugDDI.d199.s8.p23" e1="DrugDDI.d199.s8.e4" e2="DrugDDI.d199.s8.e6" interaction="?"/><pair id="DrugDDI.d199.s8.p24" e1="DrugDDI.d199.s8.e4" e2="DrugDDI.d199.s8.e7" interaction="?"/><pair id="DrugDDI.d199.s8.p25" e1="DrugDDI.d199.s8.e5" e2="DrugDDI.d199.s8.e6" interaction="?"/><pair id="DrugDDI.d199.s8.p26" e1="DrugDDI.d199.s8.e5" e2="DrugDDI.d199.s8.e7" interaction="?"/><pair id="DrugDDI.d199.s8.p27" e1="DrugDDI.d199.s8.e6" e2="DrugDDI.d199.s8.e7" interaction="?"/></sentence><sentence id="DrugDDI.d199.s9" origId="s9" text="They are weak inhibitors of CYP2C19 and CYP2A6, and mild-to-moderate inhibitors of CYP2C9 at therapeutic concentrations."><entity id="DrugDDI.d199.s9.e0" origId="s9.p135" charOffset="28-35" type="drug" text="CYP2C19"/><entity id="DrugDDI.d199.s9.e1" origId="s9.p137" charOffset="40-46" type="drug" text="CYP2A6"/><entity id="DrugDDI.d199.s9.e2" origId="s9.p140" charOffset="83-89" type="drug" text="CYP2C9"/><pair id="DrugDDI.d199.s9.p0" e1="DrugDDI.d199.s9.e0" e2="DrugDDI.d199.s9.e1" interaction="?"/><pair id="DrugDDI.d199.s9.p1" e1="DrugDDI.d199.s9.e0" e2="DrugDDI.d199.s9.e2" interaction="?"/><pair id="DrugDDI.d199.s9.p2" e1="DrugDDI.d199.s9.e1" e2="DrugDDI.d199.s9.e2" interaction="?"/></sentence><sentence id="DrugDDI.d199.s10" origId="s10" text="Potentiation of coumarin-type anticoagulants has been observed with prolongation of the prothrombin time/INR."><entity id="DrugDDI.d199.s10.e0" origId="s10.p143" charOffset="16-44" type="drug" text="coumarin-type anticoagulants"/></sentence><sentence id="DrugDDI.d199.s11" origId="s11" text="Bile acid sequestrants have been shown to bind other drugs given concurrently."><entity id="DrugDDI.d199.s11.e0" origId="s11.p150" charOffset="0-22" type="drug" text="Bile acid sequestrants"/><entity id="DrugDDI.d199.s11.e1" origId="s11.p156" charOffset="53-58" type="drug" text="drugs"/><pair id="DrugDDI.d199.s11.p0" e1="DrugDDI.d199.s11.e0" e2="DrugDDI.d199.s11.e1" interaction="?"/></sentence><sentence id="DrugDDI.d199.s12" origId="s12" text="Therefore, fenofibrate should be taken at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption ."><entity id="DrugDDI.d199.s12.e0" origId="s12.p160" charOffset="11-22" type="drug" text="fenofibrate"/><entity id="DrugDDI.d199.s12.e1" origId="s12.p168" charOffset="83-92" type="drug" text="bile acid"/><pair id="DrugDDI.d199.s12.p0" e1="DrugDDI.d199.s12.e0" e2="DrugDDI.d199.s12.e1" interaction="?"/></sentence><sentence id="DrugDDI.d199.s13" origId="s13" text="Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3?-hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults."><entity id="DrugDDI.d199.s13.e0" origId="s13.p173" charOffset="30-41" type="drug" text="fenofibrate"/><entity id="DrugDDI.d199.s13.e1" origId="s13.p176" charOffset="63-69" type="drug" text="TRICOR"/><entity id="DrugDDI.d199.s13.e2" origId="s13.p178" charOffset="76-87" type="drug" text="pravastatin"/><entity id="DrugDDI.d199.s13.e3" origId="s13.p193" charOffset="179-190" type="drug" text="pravastatin"/><entity id="DrugDDI.d199.s13.e4" origId="s13.p210" charOffset="330-341" type="drug" text="pravastatin"/><pair id="DrugDDI.d199.s13.p0" e1="DrugDDI.d199.s13.e0" e2="DrugDDI.d199.s13.e1" interaction="?"/><pair id="DrugDDI.d199.s13.p1" e1="DrugDDI.d199.s13.e0" e2="DrugDDI.d199.s13.e2" interaction="?"/><pair id="DrugDDI.d199.s13.p2" e1="DrugDDI.d199.s13.e0" e2="DrugDDI.d199.s13.e3" interaction="?"/><pair id="DrugDDI.d199.s13.p3" e1="DrugDDI.d199.s13.e0" e2="DrugDDI.d199.s13.e4" interaction="?"/><pair id="DrugDDI.d199.s13.p4" e1="DrugDDI.d199.s13.e1" e2="DrugDDI.d199.s13.e2" interaction="?"/><pair id="DrugDDI.d199.s13.p5" e1="DrugDDI.d199.s13.e1" e2="DrugDDI.d199.s13.e3" interaction="?"/><pair id="DrugDDI.d199.s13.p6" e1="DrugDDI.d199.s13.e1" e2="DrugDDI.d199.s13.e4" interaction="?"/><pair id="DrugDDI.d199.s13.p7" e1="DrugDDI.d199.s13.e2" e2="DrugDDI.d199.s13.e3" interaction="?"/><pair id="DrugDDI.d199.s13.p8" e1="DrugDDI.d199.s13.e2" e2="DrugDDI.d199.s13.e4" interaction="?"/><pair id="DrugDDI.d199.s13.p9" e1="DrugDDI.d199.s13.e3" e2="DrugDDI.d199.s13.e4" interaction="?"/></sentence><sentence id="DrugDDI.d199.s14" origId="s14" text="A single dose of pravastatin had no clinically important effect on the pharmacokinetics of fenofibric acid."><entity id="DrugDDI.d199.s14.e0" origId="s14.p228" charOffset="17-28" type="drug" text="pravastatin"/><entity id="DrugDDI.d199.s14.e1" origId="s14.p232" charOffset="91-106" type="drug" text="fenofibric acid"/><pair id="DrugDDI.d199.s14.p0" e1="DrugDDI.d199.s14.e0" e2="DrugDDI.d199.s14.e1" interaction="?"/></sentence><sentence id="DrugDDI.d199.s15" origId="s15" text="Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males."><entity id="DrugDDI.d199.s15.e0" origId="s15.p234" charOffset="30-41" type="drug" text="fenofibrate"/><entity id="DrugDDI.d199.s15.e1" origId="s15.p237" charOffset="64-70" type="drug" text="TRICOR"/><entity id="DrugDDI.d199.s15.e2" origId="s15.p239" charOffset="77-89" type="drug" text="atorvastatin"/><entity id="DrugDDI.d199.s15.e3" origId="s15.p253" charOffset="205-217" type="drug" text="atorvastatin"/><pair id="DrugDDI.d199.s15.p0" e1="DrugDDI.d199.s15.e0" e2="DrugDDI.d199.s15.e1" interaction="?"/><pair id="DrugDDI.d199.s15.p1" e1="DrugDDI.d199.s15.e0" e2="DrugDDI.d199.s15.e2" interaction="?"/><pair id="DrugDDI.d199.s15.p2" e1="DrugDDI.d199.s15.e0" e2="DrugDDI.d199.s15.e3" interaction="?"/><pair id="DrugDDI.d199.s15.p3" e1="DrugDDI.d199.s15.e1" e2="DrugDDI.d199.s15.e2" interaction="?"/><pair id="DrugDDI.d199.s15.p4" e1="DrugDDI.d199.s15.e1" e2="DrugDDI.d199.s15.e3" interaction="?"/><pair id="DrugDDI.d199.s15.p5" e1="DrugDDI.d199.s15.e2" e2="DrugDDI.d199.s15.e3" interaction="?"/></sentence><sentence id="DrugDDI.d199.s16" origId="s16" text="The atorvastatin Cmax values were not significantly affected by fenofibrate."><entity id="DrugDDI.d199.s16.e0" origId="s16.p255" charOffset="4-16" type="drug" text="atorvastatin"/><entity id="DrugDDI.d199.s16.e1" origId="s16.p259" charOffset="64-75" type="drug" text="fenofibrate"/><pair id="DrugDDI.d199.s16.p0" e1="DrugDDI.d199.s16.e0" e2="DrugDDI.d199.s16.e1" interaction="?"/></sentence><sentence id="DrugDDI.d199.s17" origId="s17" text="The pharmacokinetics of fenofibric acid were not significantly affected by atorvastatin"><entity id="DrugDDI.d199.s17.e0" origId="s17.p261" charOffset="24-39" type="drug" text="fenofibric acid"/><entity id="DrugDDI.d199.s17.e1" origId="s17.p265" charOffset="75-87" type="drug" text="atorvastatin"/><pair id="DrugDDI.d199.s17.p0" e1="DrugDDI.d199.s17.e0" e2="DrugDDI.d199.s17.e1" interaction="?"/></sentence><sentence id="DrugDDI.d199.s18" origId="s18" text="."/><sentence id="DrugDDI.d199.s19" origId="s19" text="?"/></document>